Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation in YAP-Driven Cancer Metastasis

Study Background and Research Question

Post-translational modifications (PTMs) critically modulate protein function, localization, and cellular signaling. Among these, protein S-palmitoylation—reversible attachment of palmitate to cysteine residues—has emerged as a key regulatory process with distinct roles in health and disease. The enzymes responsible for S-palmitoylation, DHHC palmitoyltransferases, have attracted growing attention in oncology, as aberrant palmitoylation events are increasingly implicated in tumor progression and metastasis. However, the specific substrates and cancer-specific activities of individual DHHC enzymes remain largely uncharacterized. The current study by Yang Tian et al. (2025) addresses this gap by examining the role of DHHC9 in adenocarcinoma metastasis and its impact on Hippo pathway signaling.

Key Innovation from the Reference Study

The central innovation of this work lies in defining a novel signaling axis: DHHC9-mediated palmitoylation of STRN4 governs YAP nuclear translocation and downstream transcriptional activation in cancer cells. Importantly, the authors identify two small molecules, Treprostinil and 10-HCPT, as potent inhibitors of DHHC9, demonstrating that pharmacological disruption of this palmitoylation event can suppress cancer cell migration. This finding not only clarifies the functional significance of DHHC9 in tumor biology but also establishes the DHHC9-STRN4-YAP pathway as a promising therapeutic target for metastatic cancers.

Methods and Experimental Design Insights

The study employs a multi-layered experimental strategy integrating genetic, proteomic, and pharmacological approaches:

• Genetic manipulation: DHHC9 expression was knocked down in colorectal and lung adenocarcinoma cell lines using shRNA techniques. Functional assays assessed changes in cell migration and metastasis potential.
• Proteomic analysis: The authors utilized mass spectrometry-based proteomics to identify substrates of DHHC9, focusing on palmitoylation targets. STRN4 emerged as a principal candidate, with cysteine 701 identified as the palmitoylation site.
• Signal transduction assays: Downstream effects on the Hippo pathway were evaluated by monitoring YAP phosphorylation status, subcellular localization, and target gene expression (CCN1, CCN2, ANKRD1).
• Pharmacological inhibition: Small-molecule screening led to the identification and validation of Treprostinil and 10-HCPT as DHHC9 inhibitors. Their effects on palmitoylation, YAP activity, and cancer cell migration were tested both in vitro and in vivo.
• In vivo metastasis models: Mouse models of tumor metastasis were used to corroborate in vitro findings, strengthening the translational relevance of the DHHC9-STRN4-YAP axis.

Protocol Parameters

• DHHC9 knockdown: Lentiviral shRNA transduction; validation by qPCR and Western blot; use in both colorectal and lung adenocarcinoma cell lines.
• Palmitoylation detection: Acyl-biotin exchange (ABE) or similar assays; confirmation by mass spectrometry to pinpoint palmitoylation sites.
• Pharmacological inhibition: Treatment of cell cultures with Treprostinil or 10-HCPT at concentrations empirically optimized to achieve DHHC9 inhibition without off-target toxicity.
• Protein extraction and protection: Use of a phosphorylation-compatible, EDTA-free protease inhibitor cocktail to maintain protein integrity and post-translational modifications during lysis (see internal article for workflow recommendations).
• In vivo metastasis: Tail vein injection of manipulated cancer cells into immunodeficient mice; assessment of metastatic foci by histology and imaging.

Core Findings and Why They Matter

The authors demonstrate that DHHC9 is essential for the palmitoylation of STRN4 at cysteine 701. Loss of DHHC9 or pharmacological inhibition results in reduced STRN4 palmitoylation, increased YAP phosphorylation, cytoplasmic retention of YAP, and diminished expression of canonical Hippo pathway targets. Functionally, these molecular changes translate to a marked reduction in cancer cell migration and metastatic colonization in vivo. In addition, the identification of Treprostinil and 10-HCPT as DHHC9 inhibitors highlights the therapeutic tractability of targeting palmitoylation-dependent oncogenic signaling.

These findings are particularly significant given the expanding recognition of dynamic S-palmitoylation as a modifiable driver of cancer progression. By elucidating the DHHC9-STRN4-YAP axis, the study provides mechanistic insight into how lipid modifications can regulate key signaling pathways and opens new avenues for pharmacological intervention in metastatic disease.

Comparison with Existing Internal Articles

Successful protein extraction and PTM analysis, such as palmitoylation and phosphorylation, depend on robust inhibition of endogenous proteases without disrupting labile modifications or metal-dependent enzymes. Internal resources—including the in-depth guide on Protease Inhibitor Cocktail EDTA-Free and the technical overview at magnetic-co-ip.com—emphasize the importance of using EDTA-free cocktails for workflows involving sensitive downstream applications like signaling pathway analysis. These insights align with the current study’s requirements for preserving phosphorylation states while analyzing protein palmitoylation and YAP-related signaling. Furthermore, the second internal article validates the compatibility of EDTA-free cocktails in kinase and PTM research, reinforcing their utility for DHHC9-STRN4-YAP pathway investigations.

Limitations and Transferability

While the study presents compelling evidence for the DHHC9-STRN4-YAP axis in colorectal and lung adenocarcinoma models, several limitations should be considered. First, the research focuses on a subset of cancer types, and the universality of this mechanism across other tumor contexts remains untested. Second, although two small-molecule inhibitors of DHHC9 are identified and validated in preclinical models, further work is necessary to evaluate their efficacy, specificity, and safety in clinical settings. Additionally, the study relies on established cell lines and xenograft models, which, while informative, may not capture the full heterogeneity of human metastatic disease. Finally, detailed structural and biophysical studies would be beneficial to enhance the rational design of next-generation DHHC9 inhibitors.

Research Support Resources

For researchers aiming to study palmitoylation, phosphorylation, and associated signaling pathways as seen in the DHHC9-STRN4-YAP axis, maintaining protein integrity during extraction is essential. Use of a phosphorylation-compatible, EDTA-free protease inhibitor cocktail—such as the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1007) from APExBIO—can help prevent unwanted proteolysis while preserving divalent cation-dependent processes. This approach aligns with recommendations from recent internal analyses and supports advanced workflows in cancer signaling research.